DrugsControl Media Services

News Detail

Patent office rejects J&J TB drug Bedaquiline monopoly beyond primary patent’s expiry (24-03-2023)

New Delhi, 24 March 2023: The Indian Patent Office on Thursday rejected US pharmaceutical firm Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the TB drug bedaquiline beyond the primary patent’s expiry this July, according to people famili......
View Details

Source : Livemint
TB J&J Bedaquiline TB medicine primary patent’s expiry

Related News